Keisuke Taniuchi, President and Representative Director of our company, made a presentation entitled “Identification of biomarkers to predict the efficacy of preoperative chemotherapy for pancreatic cancer” at a panel discussion of JDDW 2024 (32nd Digestive Disease Week) held in Kobe, Japan, from October 31 to November 2, 2024. In the general discussion that followed the presentation, Taniuchi exchanged opinions with other speakers on the possibility of personalized medicine using biomarkers, optimization of preoperative treatment, and the need to develop new treatment methods. We will continue to contribute to the advancement of preoperative treatment for pancreatic cancer patients who are eligible for surgery by accelerating the validation of biomarkers through multicenter collaborative research and the development of new preoperative treatment methods.